Together, these findings suggest that specific metabolites produced by intestinal bacteria can activate critical targets such as NF-κB, PI3K/AKT, and ErbB2/ErbB3, thereby contributing to the development of colorectal cancer. Here, ERBB2 is linked to colorectal cancer.